NSCLC with malignant epidural spinal cord compression (MESCC): new motor deficit, sensory...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-NSCLC-CORD-COMPRESSION |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Red Flag Origin
| Definition | NSCLC with malignant epidural spinal cord compression (MESCC): new motor deficit, sensory level, bowel/bladder dysfunction, severe back pain with vertebral metastasis on imaging — neurosurgical/radiation emergency |
|---|---|
| Clinical direction | hold |
| Category | organ-dysfunction |
| Shifts algorithm | ALGO-NSCLC-METASTATIC-1L |
Trigger Logic
{
"any_of": [
{
"finding": "spinal_cord_compression",
"value": true
},
{
"finding": "new_motor_deficit_with_back_pain",
"value": true
},
{
"finding": "vertebral_metastasis_with_canal_invasion",
"value": true
},
{
"finding": "bowel_bladder_dysfunction_acute",
"value": true
}
],
"type": "composite"
}
Notes
Per NCCN-NSCLC + NCCN supportive-care: dexamethasone 10 mg IV bolus + 4 mg q6h, urgent MRI whole spine, neurosurgery/radiation oncology consult within 24 h. Surgical decompression + RT if surgical candidate (Patchell criteria); RT alone otherwise. Time to motor deficit ≤24 h is functional-recovery cutoff. Direction HOLD on systemic therapy until cord stabilized. Priority 8 (matches PMBCL airway). STUB — requires clinical co-lead signoff.
Used By
Indications
IND-NSCLC-2L-BRAF-V600E-DAB-TRAM- IND-NSCLC-2L-BRAF-V600E-DAB-TRAMIND-NSCLC-2L-DATO-DXD- IND-NSCLC-2L-DATO-DXDIND-NSCLC-2L-DOCETAXEL-RAMUCIRUMAB- IND-NSCLC-2L-DOCETAXEL-RAMUCIRUMABIND-NSCLC-2L-EGFR-EX20INS-AMIVANTAMAB- IND-NSCLC-2L-EGFR-EX20INS-AMIVANTAMABIND-NSCLC-2L-EGFR-POST-OSI-AMI-LAZ- IND-NSCLC-2L-EGFR-POST-OSI-AMI-LAZIND-NSCLC-2L-HER2-MUT-T-DXD- IND-NSCLC-2L-HER2-MUT-T-DXDIND-NSCLC-2L-KRAS-G12C-ADAGRASIB- IND-NSCLC-2L-KRAS-G12C-ADAGRASIBIND-NSCLC-2L-KRAS-G12C-SOTORASIB- IND-NSCLC-2L-KRAS-G12C-SOTORASIBIND-NSCLC-2L-MET-AMP-CAPMATINIB- IND-NSCLC-2L-MET-AMP-CAPMATINIBIND-NSCLC-2L-MET-EX14-CAPMATINIB- IND-NSCLC-2L-MET-EX14-CAPMATINIBIND-NSCLC-2L-MET-EX14-TEPOTINIB- IND-NSCLC-2L-MET-EX14-TEPOTINIBIND-NSCLC-2L-NTRK-LAROTRECTINIB- IND-NSCLC-2L-NTRK-LAROTRECTINIBIND-NSCLC-2L-PD-L1-POST-IO-DOCETAXEL- IND-NSCLC-2L-PD-L1-POST-IO-DOCETAXELIND-NSCLC-2L-RET-FUSION-SELPERCATINIB- IND-NSCLC-2L-RET-FUSION-SELPERCATINIBIND-NSCLC-2L-ROS1-POST-CRIZ-ENTRECTINIB- IND-NSCLC-2L-ROS1-POST-CRIZ-ENTRECTINIBIND-NSCLC-2L-ROS1-REPOTRECTINIB- IND-NSCLC-2L-ROS1-REPOTRECTINIBIND-NSCLC-3L-DRIVER-BEYOND-2L- IND-NSCLC-3L-DRIVER-BEYOND-2LIND-NSCLC-3L-OSI-FAILURE-AMI- IND-NSCLC-3L-OSI-FAILURE-AMIIND-NSCLC-ALK-1L-ENSARTINIB- IND-NSCLC-ALK-1L-ENSARTINIBIND-NSCLC-ALK-2L-LORLATINIB- IND-NSCLC-ALK-2L-LORLATINIBIND-NSCLC-ALK-MAINT-ALECTINIB- IND-NSCLC-ALK-MAINT-ALECTINIBIND-NSCLC-ALK-MET-1L- IND-NSCLC-ALK-MET-1LIND-NSCLC-BRAF-V600E-1L-DAB-TRAM- IND-NSCLC-BRAF-V600E-1L-DAB-TRAMIND-NSCLC-EGFR-MAINT-OSIMERTINIB- IND-NSCLC-EGFR-MAINT-OSIMERTINIBIND-NSCLC-EGFR-MUT-MET-1L- IND-NSCLC-EGFR-MUT-MET-1LIND-NSCLC-EGFR-POST-OSI-PATRITUMAB-DXD- IND-NSCLC-EGFR-POST-OSI-PATRITUMAB-DXDIND-NSCLC-ELDERLY-CARBO-PEM-MOD- IND-NSCLC-ELDERLY-CARBO-PEM-MODIND-NSCLC-KRAS-G12C-MET-2L- IND-NSCLC-KRAS-G12C-MET-2LIND-NSCLC-MET-EX14-1L-CAPMATINIB- IND-NSCLC-MET-EX14-1L-CAPMATINIBIND-NSCLC-NRG1-ZENOCUTUZUMAB- IND-NSCLC-NRG1-ZENOCUTUZUMABIND-NSCLC-NTRK-FUSION-1L-LAROTRECTINIB- IND-NSCLC-NTRK-FUSION-1L-LAROTRECTINIBIND-NSCLC-PDL1-22C3-PEMBRO-CLONE-SPECIFIC- IND-NSCLC-PDL1-22C3-PEMBRO-CLONE-SPECIFICIND-NSCLC-PDL1-HIGH-MET-1L- IND-NSCLC-PDL1-HIGH-MET-1LIND-NSCLC-PDL1-LOW-NONSQ-MET-1L- IND-NSCLC-PDL1-LOW-NONSQ-MET-1LIND-NSCLC-PEMBRO-MAINTENANCE-POST-CHEMO- IND-NSCLC-PEMBRO-MAINTENANCE-POST-CHEMOIND-NSCLC-RET-FUSION-1L-SELPERCATINIB- IND-NSCLC-RET-FUSION-1L-SELPERCATINIBIND-NSCLC-ROS1-1L-REPOTRECTINIB- IND-NSCLC-ROS1-1L-REPOTRECTINIBIND-NSCLC-STAGE-III-PACIFIC- IND-NSCLC-STAGE-III-PACIFICIND-NSCLC-TMB-HIGH-MET-1L-PEMBRO-MONO- IND-NSCLC-TMB-HIGH-MET-1L-PEMBRO-MONOIND-PAN-NTRK-2L-REPOTRECTINIB- IND-PAN-NTRK-2L-REPOTRECTINIB